What is the next step in managing a patient with impaired renal function, creatinine level of 1.17, GFR of 58, and no nephrotoxic medications?

Management of Stage 3 CKD (GFR 58 mL/min/1.73m²)

With a GFR of 58 mL/min/1.73m² and creatinine 1.17 mg/dL, the next step is to confirm the diagnosis with repeat testing in 3 months, identify and address the underlying cause, implement cardiovascular risk reduction strategies, and initiate nephroprotective measures—nephrology referral is not yet indicated at this stage unless specific high-risk features develop. 1

Confirm the Diagnosis

• Repeat serum creatinine and calculate eGFR in 3 months to confirm chronic kidney disease, as a single elevated creatinine may not represent true CKD. 1
• Stage 3 CKD is defined as GFR 30-59 mL/min/1.73m² persisting for at least 3 months. 1
• Do not rely on serum creatinine alone—always use eGFR calculated by the MDRD or CKD-EPI equation, as creatinine can appear "normal" despite significantly reduced kidney function, especially in elderly patients, women, and those with reduced muscle mass. 1

Identify the Underlying Cause

• Obtain urinalysis with microscopy to assess for proteinuria, hematuria, pyuria, or casts. 1
• Measure urine albumin-to-creatinine ratio (ACR) on a spot morning urine sample—values >30 mg/g indicate kidney damage and significantly increase cardiovascular risk. 1
• Obtain renal ultrasound to assess kidney size, rule out obstruction, and evaluate for structural abnormalities such as polycystic kidney disease. 1
• Review medication history for nephrotoxic agents (NSAIDs, aminoglycosides, proton pump inhibitors, lithium) and discontinue if possible. 2
• Assess for systemic diseases: diabetes (HbA1c), hypertension (blood pressure control), autoimmune conditions (ANA, complement levels if indicated). 1

Nephrology Referral Criteria—NOT Yet Met

You do NOT need to refer to nephrology at this time unless specific high-risk features develop: 1

• GFR <30 mL/min/1.73m² (Stage 4-5 CKD)
• Proteinuria >1 g/day (ACR ≥60 mg/mmol or PCR ≥100 mg/mmol)
• Rapid progression: decline in eGFR >20% within 3-6 months or >5 mL/min/1.73m² per year
• Persistent hematuria with proteinuria
• Refractory hypertension requiring ≥4 antihypertensive agents
• Recurrent nephrolithiasis or hereditary kidney disease
• Unexplained kidney dysfunction in a young patient

Implement Nephroprotective Measures

Blood Pressure Control

• Target BP <130/80 mmHg in patients with CKD, especially if proteinuria is present. 1
• Initiate ACE inhibitor or ARB as first-line therapy if proteinuria (ACR >30 mg/g) or diabetes is present, as these agents reduce proteinuria and slow CKD progression. 2
• Monitor serum creatinine and potassium 1-2 weeks after starting ACE inhibitor/ARB—an increase in creatinine up to 30% is acceptable and does not indicate progressive renal deterioration. 1, 2
• Discontinue ACE inhibitor/ARB if creatinine increases >30% or if hyperkalemia (K >5.5 mEq/L) develops despite dietary restriction. 2

Avoid Nephrotoxic Agents

• Permanently discontinue NSAIDs (ibuprofen, naproxen, ketorolac) as they reduce renal blood flow and accelerate CKD progression. 2
• Avoid or minimize IV contrast exposure—if unavoidable, use iso-osmolar contrast and ensure adequate hydration. 1
• Adjust doses of all renally cleared medications (antibiotics, antivirals, anticoagulants) based on eGFR. 3

Cardiovascular Risk Reduction

• Initiate statin therapy regardless of baseline LDL, as CKD is a cardiovascular disease equivalent and most patients with Stage 3 CKD die from cardiovascular events rather than progressing to dialysis. 1
• Optimize glycemic control if diabetic (HbA1c <7%) to slow progression of diabetic nephropathy. 1
• Encourage smoking cessation, as smoking accelerates CKD progression. 1

Monitor for Complications of CKD

Anemia

• Check CBC, iron studies (ferritin, transferrin saturation), vitamin B12, and folate if hemoglobin <13 g/dL (men) or <12 g/dL (women). 3
• Consider erythropoiesis-stimulating agents (ESAs) if hemoglobin <10 g/dL and iron replete, though this is typically managed by nephrology. 3

Mineral Bone Disease

• Check serum calcium, phosphorus, parathyroid hormone (PTH), and 25-hydroxyvitamin D at baseline and annually. 3
• Supplement vitamin D if deficient (<30 ng/mL). 3
• Restrict dietary phosphorus if hyperphosphatemia develops (phosphorus >4.5 mg/dL). 3

Metabolic Acidosis

• Check serum bicarbonate—if <22 mEq/L, consider sodium bicarbonate supplementation (650 mg PO TID) to slow CKD progression. 3

Hyperkalemia

• Monitor serum potassium every 3-6 months—if >5.5 mEq/L, restrict dietary potassium (<2 g/day) and discontinue potassium-sparing diuretics (spironolactone, amiloride) and potassium supplements. 3, 2

Common Pitfalls to Avoid

• Do not use 24-hour urine creatinine clearance—it is less accurate than eGFR calculated from serum creatinine and is inconvenient for patients. 1
• Do not assume "normal" creatinine means normal kidney function—a creatinine of 1.17 mg/dL can correspond to GFR as low as 40-60 mL/min/1.73m² depending on age, sex, and muscle mass. 1
• Do not abruptly stop ACE inhibitors/ARBs if creatinine rises <30%—this is an expected hemodynamic effect and does not indicate harm. 1, 2
• Do not refer to nephrology prematurely—Stage 3 CKD can be effectively managed in primary care unless high-risk features develop. 1